936845-86-2 Usage
Uses
Used in Pharmaceutical Development:
1-Piperazinecarboxylic acid, 4-[6-[(5-ethenyl-2-thiazolyl)amino]-2-methyl-4-pyrimidinyl]-, 1,1-dimethylethyl ester is used as a precursor in the synthesis of pharmaceuticals for its potential to target specific biological pathways or disorders. The presence of thiazole and pyrimidine in its structure suggests that it may interact with various biological targets, offering a broad scope for medicinal chemistry applications.
Used in Drug Design and Medicinal Chemistry:
In the field of drug design and medicinal chemistry, 1-Piperazinecarboxylic acid, 4-[6-[(5-ethenyl-2-thiazolyl)amino]-2-methyl-4-pyrimidinyl]-, 1,1-dimethylethyl ester is utilized as a building block for creating novel drug candidates. Its unique structural features allow for the fine-tuning of pharmacokinetic and pharmacodynamic properties, which is crucial for the development of effective and safe therapeutic agents.
Used in Research and Development:
1-Piperazinecarboxylic acid, 4-[6-[(5-ethenyl-2-thiazolyl)amino]-2-methyl-4-pyrimidinyl]-, 1,1-dimethylethyl ester serves as a valuable tool in research and development settings. It is employed in experimental studies aimed at understanding its mechanism of action, as well as in the screening of potential therapeutic effects against various diseases and conditions. 1-Piperazinecarboxylic acid, 4-[6-[(5-ethenyl-2-thiazolyl)amino]-2-methyl-4-pyrimidinyl]-, 1,1-dimethylethyl ester's role in research is vital for advancing the knowledge of drug discovery and development processes.
Check Digit Verification of cas no
The CAS Registry Mumber 936845-86-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,6,8,4 and 5 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 936845-86:
(8*9)+(7*3)+(6*6)+(5*8)+(4*4)+(3*5)+(2*8)+(1*6)=222
222 % 10 = 2
So 936845-86-2 is a valid CAS Registry Number.
936845-86-2Relevant academic research and scientific papers
THIAZOLE INHIBITORS TARGETING RESISTANT AND KINASE MUTATIONS
-
Page/Page column 49-50, (2010/11/27)
A compound is provided, having the general structure (A): wherein A is an aryl or heteroaryl group, Y is a hydrophobic linking moiety, and L is a substitutent. The compound (A) can be used for treatment of various angiogenic-associated or hematologic disorders, such as myeloproliferative disorders in patients who do not respond to kinase-inhibition therapy that comprises administering currently used medications.
